In a report released on April 22, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price target of $478.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Stephen Baxter’s rating is based on Elevance Health’s strong financial performance in the first quarter of 2025, which exceeded previous expectations. The company’s adjusted earnings per share (EPS) of $11.97 were consistent with preannouncements and surpassed both Wells Fargo Securities and consensus estimates. Additionally, Elevance Health’s operating revenue showed a significant year-over-year increase of 15.4%, outperforming the estimates.
Furthermore, the company’s diverse revenue streams, including CarelonRx and Carelon Services, demonstrated robust growth. CarelonRx revenue increased by 25.4% year-over-year, while Carelon Services revenue surged by 63.0%. These positive financial metrics, coupled with a reaffirmation of 2025 guidance, underpin Baxter’s confidence in the company’s future performance, justifying the Buy rating.
In another report released on April 23, Barclays also maintained a Buy rating on the stock with a $522.00 price target.
ELV’s price has also changed slightly for the past six months – from $419.840 to $415.900, which is a -0.94% drop .